Konstantinos Ioannis Avgerinos1,2,3, Grigorios Kalaitzidis4,5, Antonia Malli6,5, Dimitrios Kalaitzoglou6,5, Pavlos Gr Myserlis7,5, Vasileios-Arsenios Lioutas8. 1. 251 Hellenic Airforce General Hospital, Kanellopoulou 3, 11525, Athens, Greece. kwstas-avge@hotmail.com. 2. Department of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece. kwstas-avge@hotmail.com. 3. Society of Junior Doctors, Athens, Greece. kwstas-avge@hotmail.com. 4. Department of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece. 5. Society of Junior Doctors, Athens, Greece. 6. Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece. 7. 401 General Army Hospital, Athens, Greece. 8. Department of Neurology, Division of Cerebrovascular Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.
Abstract
BACKGROUND AND AIMS: Due to common pathophysiological findings of Alzheimer's disease (AD) with diabetes mellitus (DM), insulin has been suggested as a possible treatment of AD or mild cognitive impairment (MCI). A safe alternative of IV insulin is intranasal (IN) insulin. The aim of this systematic review is to investigate the effects of IN insulin on cognitive function of patients with either AD or MCI. METHODS: A literature search of the electronic databases Medline, Scopus and CENTRAL was performed to identify RCTs investigating the effect of IN insulin administration on cognitive tasks, in patients with AD or MCI. RESULTS: Seven studies (293 patients) met our inclusion criteria. Most studies showed that verbal memory and especially story recall was improved after IN insulin administration. Sometimes the effect was restricted for apoe4 (-) patients. Intranasal insulin did not affect other cognitive functions. However, there were some positive results in functional status and daily activity. Data suggested that different insulin types and doses may have different effects on different apoe4 groups. In addition, the effects of treatment on Αβ levels differed from study to study. Finally, IN insulin resulted in minor adverse effects. CONCLUSIONS: Intranasal insulin improved story recall performance of apoe4 (-) patients with AD or MCI. Other cognitive functions were not affected, but there were some positive results in functional status and daily activity. Since IN insulin is a safe intervention, future studies should be conducted with larger doses and after proper selection of patients and insulin types.
BACKGROUND AND AIMS: Due to common pathophysiological findings of Alzheimer's disease (AD) with diabetes mellitus (DM), insulin has been suggested as a possible treatment of AD or mild cognitive impairment (MCI). A safe alternative of IV insulin is intranasal (IN) insulin. The aim of this systematic review is to investigate the effects of IN insulin on cognitive function of patients with either AD or MCI. METHODS: A literature search of the electronic databases Medline, Scopus and CENTRAL was performed to identify RCTs investigating the effect of IN insulin administration on cognitive tasks, in patients with AD or MCI. RESULTS: Seven studies (293 patients) met our inclusion criteria. Most studies showed that verbal memory and especially story recall was improved after IN insulin administration. Sometimes the effect was restricted for apoe4 (-) patients. Intranasal insulin did not affect other cognitive functions. However, there were some positive results in functional status and daily activity. Data suggested that different insulin types and doses may have different effects on different apoe4 groups. In addition, the effects of treatment on Αβ levels differed from study to study. Finally, IN insulin resulted in minor adverse effects. CONCLUSIONS: Intranasal insulin improved story recall performance of apoe4 (-) patients with AD or MCI. Other cognitive functions were not affected, but there were some positive results in functional status and daily activity. Since IN insulin is a safe intervention, future studies should be conducted with larger doses and after proper selection of patients and insulin types.
Authors: Christian Benedict; Manfred Hallschmid; Astrid Hatke; Bernd Schultes; Horst L Fehm; Jan Born; Werner Kern Journal: Psychoneuroendocrinology Date: 2004-11 Impact factor: 4.905
Authors: D Lalej-Bennis; J Boillot; C Bardin; P Zirinis; A Coste; E Escudier; F Chast; R Peynegre; J L Selam; G Slama Journal: Diabet Med Date: 2001-08 Impact factor: 4.359
Authors: S Craft; S Asthana; G Schellenberg; L Baker; M Cherrier; A A Boyt; R N Martins; M Raskind; E Peskind; S Plymate Journal: Ann N Y Acad Sci Date: 2000-04 Impact factor: 5.691
Authors: Carol A Colton; Leila K Needham; Candice Brown; Danielle Cook; Karima Rasheed; James R Burke; Warren J Strittmatter; Donald E Schmechel; Michael P Vitek Journal: J Neuroimmunol Date: 2004-02 Impact factor: 3.478
Authors: L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn Journal: JAMA Date: 1997 Oct 22-29 Impact factor: 56.272
Authors: B Galindo-Mendez; J A Trevino; R McGlinchey; C Fortier; V Lioutas; P Novak; C S Mantzoros; L Ngo; V Novak Journal: Contemp Clin Trials Date: 2020-01-07 Impact factor: 2.226